Patent ID: 11896615
Assignee: JUNO THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  G | IPC A  C  G

Claim 0:
1. A method of treatment of cancer in a subject in need thereof, comprising:
(a) administering a T cell therapy to the subject having cancer; and
(b) administering to the subject a therapeutically effective amount of an inhibitor of indoleamine-pyrrole 2,3-dioxygenase 1 (IDO1) subsequent to the initiation of administration of the T cell therapy,
wherein the T cell therapy comprises an engineered T cell comprising a recombinant receptor that specifically binds to an antigen, wherein the recombinant receptor is a chimeric antigen receptor (CAR) or a transgenic T cell receptor (TCR),
wherein the inhibitor of IDO1 is administered within 14 days subsequent to the initiation of the T cell therapy,
wherein, prior to the administration of the T cell therapy, the subject has not been administered an IDO inhibitor for treatment of cancer, and
wherein the cancer comprises a tumor comprising cells negative for IDO1 prior to the initiation of administration of the T cell therapy.